Aktie A3DFK3 MAXO CAP
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen MAXO CAP

Aktien

A3DFK3

US57778T1060

JMAC

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Maxpro Capital Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022
Apollomics Announces Completion of Business Combination and Listing on Nasdaq
Maxpro Capital Acquisition Corp.(NasdaqGM:JMAC) dropped from NASDAQ Composite Index
Apollomics, Inc. completed the acquisition of Maxpro Capital Acquisition Corp. from MP One Investment LLC and others in a reverse merger.
MAXPRO CAPITAL ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination
Maxpro Capital Acquisition Extends Deadline to Complete Business Combination
MAXPRO CAPITAL ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Maxpro Capital Acquisition Corp. announced that it has received $0.5 million in funding from MP One Investment LLC
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations
Apollomics Gets Orphan Drug Designation for Vebreltinib to Treat Lung Cancer
MAXPRO CAPITAL ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Maxpro Capital Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
MAXPRO CAPITAL ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Other Events, Financial Statements and Exhibits (form 8-K)
Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination
MAXPRO CAPITAL ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form 8-K)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DFK3 Aktie
  4. Nachrichten MAXO CAP
  5. Andere Sprachen